30 closest matches · ranked by relevance
COVID-19 · SARS-CoV-2
Primary: Number of Participants With Solicited Local Adverse Events (AE) During 7 Days After Vaccination — 5; 9; 16; 19 Participants
Covid19
Primary: Assessment of Seroconversion, Defined as Development of Immunoglobulin G (IgG) Antibodies Against Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) After…
COVID-19 · SARS-CoV-2
Primary: Number of Participants With Adverse Events of Special Interest (AESIs) From Study Vaccination Through the End of the Study — 1; 3; 2; 0 Participants
Kidney Transplant Recipients · Liver Transplant Recipients
Primary: The -Fold Change in Antibody Titer (Using the Roche Elecsys® Anti-SARS-CoV-2 S Assay) From Before Receiving the Study Dose of Vaccine to 30 Days After the Study Dose of…
COVID-19 · Vaccine-Preventable Diseases · SARS CoV 2 Infection
Primary: Number of Symptomatic SARS-CoV-2 Infections Between Randomized, Study-vaccinated Participants and the Comparator Group — 48; 94 Participants
Immunocompromised · Immunosuppressed · Covid-19
Primary: Incidence Rate of Breakthrough Cases of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection — 0.89; 0.34 Events per 100 person-years
COVID-19 · COVID-19 Immunisation
Primary: Frequency of Any Medically-attended Adverse Events (MAAEs) — 7; 6; 5; 7 Participants
Solid Tumor Malignancy · Hematologic Malignancy · Leukemia
Primary: Number of Participants With Grades 1-5 Solicited (Expected) and/or Unsolicited (Unexpected) Adverse Events (AE's): Initial Phase — 0; 0; 1; 0 Participants
Quality of Life · Injection Site Reaction · Adverse Drug Event
Primary: Total Number of Participants With Moderate or More Severe Fever, Chills, Myalgia, or Arthralgia in the Simultaneous Group and the Sequential Group Following Both…
Immunodeficiencies · Immune Dysregulations
Primary: Change in S and Receptor Binding Domain (RBD) Immunoglobulin G (IgG) Antibody Titer From Baseline Depending on Vaccine Manufacturer and Platform — 0.447333; 2.10678…
Covid19
Primary: Number of Participants With Emergency Center (EC) Encounters and/or Hospitalizations With Positive COVID-19 Test — 10880; 825; 129 Participants
COVID - 19
Primary: Geometric Mean (GM) of Interferon-gamma (IFN-γ) Response Against the SARS-CoV-2 Virus at Baseline — 19.6; 14; 12.6 SFCs/10⁶ PBMCs
Immunosuppression · COVID-19
Primary: Change in Antibody Concentration From Baseline (Visit 1) at 1 Month (Visit 2) — 22968.5; 66639 Endotoxin Units per milliliter (EU/mL)
SARS-CoV-2 Infection · COVID-19 · SARS-CoV-2 Acute Respiratory Disease
Primary: All Parts - Percentage of Participants Reporting Local Reactions at the Injection Site (Pain, Tenderness, Erythema/Redness, Induration/Swelling) — 19; 20; 17; 19…
Kidney Transplant Recipients
Primary: Proportion of Recipients Who Achieve an Antibody Response >50 U/mL After the Third Dose of mRNA COVID-19 Vaccine — 69.1 Percentage of participants with response
COVID-19 · SARS-CoV-2
Primary: Number of Participants With Binary Response — 73; 130 Participants — p=<0.001
SARS-CoV-2 Infection · COVID-19
Primary: Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Phase 1 — 0; 0; 8.3; 0 Percentage of participants
SARS-CoV-2
Primary: The Number of Participants With Serious Adverse Events Following Administration of ADM03820 to the Final Visit — 1; 1; 0; 0 Participants
Influenza · COVID-19
Primary: Cohort 1: Percentage of Participants With Any Local Reactions for up to 7 Days Following Vaccination in Investigational Vaccine Extremity — 74.7; 59.1 Percentage of…
Influenza · COVID-19
Primary: Percentage of Participants With HAI Seroconversion — 53.3; 52.6; 0.9; 33.5 percentage of participants — p=0.938
COVID-19
Primary: Percentage of Participants With Seroresponse to the Spike (S) Antigen of AZD1222 as Measured by Meso Scale Discovery (MSD) Serology Assay — 100.0; 0.0; 100.0; 0.0…
SARS-CoV-2 Infection · COVID-19
Primary: Geometric Mean Titers (GMTs) of Full-Length S-Binding IgG Concentrations of Lyophilized Formulation SDVs and Frozen-Liquid Formulation in MDVs 1 Month After Dose 2…
COVID-19
Primary: Phase 2 and Phase 3 (Cohorts 1, 2 and Comparator): Number of Participants With Immediate Unsolicited Adverse Events (AEs) — 2; 1; 1; 0 Participants
SARS-CoV-2 Infection · COVID-19
Primary: Cohort 1: Percentage of Participants Reporting Local Reactions Within 7 Days After Study Vaccination — 5.8; 5.9; 3.8; 3.9 Percentage of participants
SARS-CoV-2
Primary: Number of Serious Adverse Events — 0; 0; 0; 0 serious adverse events
COVID-19
Primary: Groups 2a and 2b and ARCT-154-J01 Historical Control: Geometric Mean Titers (GMT) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody…
Covid19
Primary: Number of Participants Who Became Less Hesitant About the COVID-19 Vaccine After Receiving a Physician Message — 23; 26; 43; 35 Participants
COVID-19
Primary: Number of Participants With Any Solicited Administration Site Events — 8; 0; 10; 1 Participants
Covid-19 Prevention
Primary: Cohorts 1a and 1b: Number of Participants With Solicited Local (Injection Site) Adverse Events (AEs) for 7 Days After Vaccination 1 in the Primary Regimen — 50; 50; 57…
SARS CoV 2 Infection
Primary: Proportion of Patients With Treatment-emergent Adverse Events, Serious Adverse Events, and Adverse Events of Specific Interest — 28; 27; 3; 3 Participants